Company: HRTX
Filing Date: 2025-06-18
Form Type: 8-K
Source: 0000950170-25-087555
Chunk: 1

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-06-18
Form: 8-K
Item: Item 5.07
Chunk 1
---
      35,904,582  
  Mr. Johnson                   81,742,495      2,302,736       53,691      35,904,582  
  Mr. Kaseta                    81,849,779      2,202,021       47,122      35,904,582  
  Mr. Morgan                    82,815,802      1,225,808       57,312      35,904,582  
  Mr. Waage                     79,359,803      4,687,202       51,917      35,904,582  

Proposal 2: The Company’s stockholders ratified the appointment of Withum Smith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025:

          For        Against      Abstain      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────
  118,578,049      1,033,191      392,264                     0  

Proposal 3: The Company’s stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company’s Named Executive Officers during the fiscal year ended December 31, 2024:

         For        Against        Abstain      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────────
  79,260,872      3,528,575      1,309,475            35,904,582  

Proposal 4: The Company’s stockholders approved, on a nonbinding advisory basis, conducting future advisory votes on the compensation paid to the Company’s Named Executive Officers on an annual basis:

      1 Year      2 Years        3 Years        Abstain      Broker Non-Votes  
 ───────────────────────────────────────────────────────────────────────────────
  80,506,750      326,356      2,218,888      1,046,928            35,904,582  

In light of this vote and consistent with the Company’s recommendation, the Company intends to include a non-binding, advisory vote to consider the compensation paid to its Named Executive Officers every year until the next required vote on the frequency of the non-binding advisory vote to approve the compensation paid to Company’s Named Executive Officers. The Company is required to hold a vote on frequency every six years.

  Exhibit No.      Description